8-K

   1
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                             ----------------------

                                    FORM 8-K

                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


                Date of Report (Date of earliest event reported)
                                 AUGUST 26, 1997


                              T CELL SCIENCES, INC.
               --------------------------------------------------
               (Exact name of registrant as specified in charter)


          DELAWARE                      0-15006                   13-3191702
- ----------------------------    -----------------------      -------------------
(State or other jurisdiction    (Commission file number)        (IRS employer
        of incorporation)                                    identification no.)


                      119 FOURTH AVENUE, NEEDHAM, MA 02194
              ---------------------------------------------------
              (Address of principal executive offices) (Zip code)


       Registrant's telephone number, including area code: (617) 433-0771
                                                           --------------





   2




ITEM 5 - OTHER EVENTS

On August 26, 1997 T Cell Sciences, Inc. ("T Cell") announced the findings of
the Superior Court of Massachusetts in litigation relating to its former
headquarters in Cambridge, Massachusetts:

NEEDHAM, Mass., Aug. 26, 1997--T Cell Sciences, Inc. (Nasdaq:TCEL) announced
today that the Superior Court of Massachusetts has entered findings of fact and
conclusions of law on a limited trial of T Cell's lawsuit against the landlord
of its former Cambridge, Massachusetts headquarters. T Cell is seeking to
recover damages it incurred as a result of the evacuation of the building due to
air quality problems caused by contamination by fireproofing fibers. The
landlord defendant has filed a counterclaim alleging T Cell has breached its
lease obligations. In its findings on the limited trial, the Court concluded
that T Cell had not proved at the limited trial that any fireproofing fibers
contaminated T Cell's space, T Cell's space was not uninhabitable because of
contamination from fireproofing fibers and T Cell was not justified in
terminating its lease on the grounds that its office and laboratories were
uninhabitable.

ITEM 7 - FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

         (c)      Exhibits

         99.1     Press Release issued August 26, 1997




   3



                                   SIGNATURES



      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                         T CELL SCIENCES, INC.



Date: August 26, 1997                    By: /s/  Una S. Ryan
                                             _______________________
                                             Una S. Ryan, Ph.D.
                                             Chief Executive Officer




   4



                                  EXHIBIT INDEX


99.1     Press Release Issued August 26, 1997.

EX-99.1

   1


                                                                    Exhibit 99.1


        Court Finds Against T Cell Sciences, Inc. in Building Litigation


NEEDHAM, Mass., Aug. 26, 1997--T Cell Sciences, Inc. (Nasdaq:TCEL) announced
today that the Superior Court of Massachusetts has entered findings of fact and
conclusions of law on a limited trial of T Cell's lawsuit against the landlord
of its former Cambridge, Massachusetts headquarters. T Cell is seeking to
recover damages it incurred as a result of the evacuation of the building due to
air quality problems caused by contamination by fireproofing fibers. The
landlord defendant has filed a counterclaim alleging T Cell has breached its
lease obligations. In its findings on the limited trial, the Court concluded
that T Cell had not proved at the limited trial that any fireproofing fibers
contaminated T Cell's space, T Cell's space was not uninhabitable because of
contamination from fireproofing fibers and T Cell was not justified in
terminating its lease on the grounds that its office and laboratories were
uninhabitable.

T Cell Sciences, Inc. is a biopharmaceutical company engaged in the discovery
and development of innovative pharmaceuticals targeting certain diseases of the
immune, inflammatory, and cardiovascular systems. The Company's lead therapeutic
program is focused on developing compounds that inhibit the inappropriate
activation of the complement cascade, which is a vital part of the body's immune
defense system. The Company is also engaged in the discovery and development of
T cell activation inhibitors for the prevention of transplant rejection and
autoimmune diseases, and a vaccine for the management of atherosclerosis.
Additional information on T Cell Sciences can be obtained through the Company's
site on the World Wide Web: http://www.tcell.com.